Regenxbio, a gene therapy company founded in 2009 through collaboration with the Penn Center for Innovation, opened a new facility at its Maryland campus. The $65 million, 132,000-square-foot gene therapy manufacturing facility will help the company elevate its in-house manufacturing of NAV Technology-based adeno-associated virus, or AAV, vectors and implement their platform suspension cell culture process.
Read the full article here: https://endpts.com/regenxbio-opens-gene-therapy-manufacturing-facility-at-its-maryland-hq/